-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Earlier, Revolution Medicines’ RASONQUE Plus Chemotherapy Shows 60.7% Confirmed ORR, 8.2% Complete Responses In 61 First-Line Metastatic Pancreatic Cancer Patients At 18.3-Month Median Follow-Up; Supports Phase 3 RASolute 303

Benzinga·11/20/2026 05:38:48
Listen to the news
  • With additional patients and longer follow-up, the combination of RASONQUE plus gemcitabine and nab-paclitaxel demonstrated deep and durable responses in the first-line treatment setting
  • Results support the ongoing Phase 3 RASolute 303 trial in patients with treatment-naïve metastatic pancreatic cancer